JOURNAL ARTICLES -

• Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. Engl J Med. 2009 Dec 3;361(23):2230-40. PMID: 19952143

• Maya Balamane, Mark A. Winters, Sudeb C. Dalai, Alexandra H. Freeman, Mark W. Traves, Dennis M. Israelski, David A. Katzenstein and Jeffrey D. Klausner Detection of HIV-1 in Saliva: Implications for Case-Identification, ClinicalMonitoring and Surveillance for Drug Resistance. The Open Virology Journal, 2010, 4, 78-83

• White EJ, McColgan B, Kassaye S, Zijenah L, Katzenstein D.Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5). AIDS. 2010 Apr 24;24(7):1063-4.PMID:20299967

• (D. Katzenstein, Chair of Biologic Outcomes Working group for the NIMH c-pol study). NIMH Collaborative HIV/STD Prevention Trial Group. Results of the NIMH collaborative HIV/sexually transmitted disease prevention trial of a community popular opinion leader intervention.J Acquir Immune Defic Syndr. 2010 Jun;54(2):204-14.PMID: 20354444

• Ziad El-Khatib, Anna Mia Ekström, Johanna Ledwaba, Lerato Mohapi, Fatima Laher, Alan Karstaedt, Salome Charalambous, Max Petzold, David Katzenstein, Lynn Morris. Viremia 1 and drug resistance among HIV-1 patients on antiretroviral treatment – a cross sectional study in Soweto, South Africa. AIDS. 2010 Jul 17;24(11):1679-87.PMID: 20453629.

• Soren Gantt, Jacquelyn Carlsson, Laura Heath, Marta E. Bull, Avinash K. Shetty, Junior Mutsvangwa, Georgina Musingwini, Godfrey Woelk, Lynn S. Zijenah, David A. Katzenstein, James I. Mullins, and Lisa M. Frenkel. Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol. 2010 Jul 21. PMID: 20660189

• Varghese V, Wang E, Babrzadeh F, Bachmann MH, Shahriar R, Liu T, Mappala SJ, Gharizadeh B, Fessel WJ, Katzenstein D, Kassaye S, Shafer RW. Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.PLoS One. 2010 Jun 7;5(6):e10992.PMID: 20539818.

• McClellan, Rena Patel, Gerard Kadzirange, Tsungai Chipato, David Katzenstein.Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe.Afr. J. Reprod. Health 2010; 14[2]: 27-35.

• Bulterys PL, Dalai SC, Katzenstein DA. Viral sequence analysis from HIV-infected mothers and infants: molecular evolution, diversity, and risk factors for mother-to-child transmission.Clin Perinatol. 2010 Dec;37(4):739-50, viii.

• Daar ES, Tierney C, Fischl MA, Sax PE, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Pappa KA, Woodward WC, Patterson K, Bolivar H, Benson CA, Collier AC; for the AIDS Clinical Trials Group Study A5202 Team. Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV Type-1: A Randomized Trial.Ann Intern Med. 2011 Feb 14. PMID:21320923

• El-Khatib Z, Ekstrom AM, Coovadia A, Abrams EJ, Petzold M, Katzenstein D, Morris L, Kuhn L. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. BMC Public Health. 2011 Feb 8;11(1):88.

• Ziad El-Khatib, Allison K. DeLong, David Katzenstein, Anna Mia Ekstrom, Johanna Ledwaba, Lerato Mohapi, Fatima Laher, Max Petzold, Lynn Morris and Rami Kantor Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa. J AIDS Clinic Res 2011, 2:2 PMID:21927716

• Susan Swindells, Hongyu Jiang, A. Lisa Mukherjee, Mark Winters, Ronald J. Bosch, David Katzenstein, and the AIDS Clinical Trials Group Lower CD4 Cell Count and Higher Virus Load, but Not Antiviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis.HIV Clin Trials 2011;12(2):79–88

• El-Khatib Z, Katzenstein D, Marrone G, Laher F, Mohapi L, Petzold M, Morris L, Ekström AM Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa. PLoS One. 2011 Mar 9;6(3):e17518. PMID: 21408071.

• Thairu L, Katzenstein D, Israelski D Operational challenges in delivering CD4 diagnostics in sub-Saharan Africa. AIDS Care. 2011 Mar 10:1-8. PMID: 21400312

• Tshabalala M, Manasa J, Zijenah LS, Rusakaniko S, Kadzirange G, Mucheche M, Kassaye S, Johnston E, Katzenstein D Surveillance of Transmitted Antiretroviral Drug Resistance among HIV-1 Infected Women Attending Antenatal Clinics in Chitungwiza, Zimbabwe.PLoS One. 2011;6(6):e21241. PMID: 21698125

• Philip L. Bulterys, Ann Chao, Sudeb C. Dalai, Christine M. Zink, Abel Dushimimana, David Katzenstein, Alfred J. Saah, and Marc BulterysPlacental Malaria and Mother-to-Child Transmission of Human Immunodeficiency Virus-1 in Rural Rwanda. Am J Trop Med Hyg. 2011 Aug;85(2):202-6. PMID:21813835

• Patel R, Ratner J, Gore-Felton C, Kadzirange G, Woelk G, Katzenstein D. HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe. AIDS Care. 2011 Sep 9. PMID 21902570

• Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Feinberg J, Tashima K, Murphy RL, Fischl MA; on behalf of the AIDS Clinical Trials Group Study A5202 Team. Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results.J Infect Dis. 2011 Oct;204(8):1191-1201. PMID: 21917892

• Kassaye SG, Katzenstein D. The point of point-of-care testing. Lancet. 2011 Oct 29;378(9802):1532-3.PMID:22035547

• Gaydos CA, Rizzo-Price PA, Balakrishnan P, Mateta P, Leon SR, Verevochkin S, Yin YP, Quinn TC, Strader LC, Pequegnat W; NIMH Collaborative HIV/STD Prevention Trial Group Impact of international laboratory partnerships on the performance of HIV/sexually transmitted infection testing in five resource-constrained countries.Int J STD AIDS. 2011 Nov;22(11):645-52.PMID: 22256336

• Saravanan S, Madhavan V, Solomon SS, Kantor R, Katzenstein D, Sivamalar S, Kumarasamy N, Smith DM, Mayer KH, Solomon S, Balakrishnan P.Reverse Transcriptase Substitution at Codons 208 and 228 Among Treatment-Experienced HIV-1 Subtype-C-Infected Indian Patients Is Strongly Associated With Thymidine Analogue Mutations.J Acquir Immune Defic Syndr. 2012 Feb 1;59(2):e26-7. PMID: 22245718

• M, Balakrishnan P, Kantor R, Solomon SS, Katzenstein D, Kumarasamy N, Yeptomi T, Sivamalar S, Rifkin S, Mayer KH, Solomon S. Viremia and HIV-1 Drug Resistance Mutations Among Patients Receiving Second-Line Highly Active Antiretroviral Therapy in Chennai, Southern India.Clin Infect Dis. 2012 Feb 22. PMID: 22323567

• Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N; for the AIDS Clinical Trials Group Study 175 Protocol Team. Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase. PLoS One. 2012;7(2):e31558. Epub 2012 Feb 21PMID: 22363673

• Banks L, Gholamin S, White E, Zijenah L, Katzenstein DA (2012) Comparing Peripheral Blood Mononuclear Cell DNA and Circulating Plasma viral RNA pol Genotypes of Subtype C HIV-1. J AIDS Clin Res. 2012 Feb;3(2):141-147. PMID:23019537

• Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira For The Southern Africa Treatment And Resistance Network Saturn. Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. AIDS Res Hum Retroviruses.AIDS Res Hum Retroviruses. 2012 Mar 12. PMID:22251009

• Bartlett JA, Ribaudo HJ, Wallis CL, Aga E, Katzenstein DK, Stevens WS, Norton MR, Klingman KL, Hosseinipour MC, Crump JA, Supparatpinyo K, Badal-Faesen S, Kallungal BA, Kumarasamy N. Lopinavir/ritonavir Monotherapy After Virologic Failure of First-line Antiretroviral Therapy in Resource-limited Settings. AIDS. 2012 2012 Jul 17;26(11):1345-54. PMID 22441252

• Huang A, Hogan JW, Istrail S, Delong A, Katzenstein DA, Kantor R. Global analysis of sequence diversity within HIV-1 subtypes across geographic regions. Future Virol. 2012 May;7(5):505-517. PMID: 22822410

• Maya Balamane,Vici Varghese, George L. Melikian, W. Jeffrey Fessel, David A. Katzenstein, and Robert W. Shafer. Panel of Prototypical Recombinant Infectious Molecular Clones Resistant to Nevirapine, Efavirenz, Etravirine, and Rilpivirine. Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. Epub 2012 Jun 4. PMID: 22664973

• Lessells R, Katzenstein D, de Oliveira T. Are subtype differences important in HIV drug resistance?Curr Opin Virol. 2012 Oct;2(5):636-43. Epub 2012 Sep 21. PMID: 23006584

• Mollan K, Daar ES, Sax PE, Balamane M, Collier AC, Fischl MA, Lalama CM, Bosch RJ, Tierney C, Katzenstein D; for the AIDS Clinical Trials Group Study A5202 Team HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status. J Infect Dis. 2012 Nov 12. PMID: 23148287.

• Rath BA, Yousef KP, Katzenstein DK, Shafer RW, Schu¨ tte C, et al. (2013) In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis. PLoS ONE 8(4): e61102. doi:10.1371/journal.pone.006110

• Rath BA, von Kleist M, Castillo ME, Kolevic L, Caballero P, Soto-Castellares G, Amedee AM, Robinson JE, Katzenstein DK, Van Dyke RB, Oberhelman RA. Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.BMC Infect Dis. 2013 Jan 2;13:1.PMID:2328023

• Swindells S, Komarow L, Tripathy S, Cain KP, MacGregor RR, Achkar JM, Gupta A, Veloso VG, Asmelash A, Omoz-Oarhe AE, Gengiah S, Lalloo U, Allen R, Shiboski C, Andersen J, Qasba SS, Katzenstein DK; AIDS Clinical Trials Group 5253 Study Team. Screening for pulmonary tuberculosis in HIV-infected individuals: AIDS Clinical Trials Group Protocol A5253. Int J Tuberc Lung Dis. 2013 Apr;17(4):532-9. PMID: 23485388

• Elizabeth White, Bryan McColgan, Seble Kassaye, Lynn Zijenah and David Katzenstein. Evolution of CXCR4 usage in subtype C HIV-1 in treatedpatients. Current Trends in Virology; 2012 volume 10 pages 85-98.

• Varghese V, Mitsuya Y, Fessel WJ, Liu TF, Melikian GL, Katzenstein DA, Schiffer CA, Holmes SP, Shafer RW. Prototypical Recombinant Multi-Protease Inhibitor Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type-1.Antimicrob Agents Chemother. 2013 Jun 24. PMID: 23796938

• Tang MW, Rhee SY, Bertagnolio S, Ford N, Holmes S, Sigaloff KC, Hamers RL, de Wit TF, Fleury HJ, Kanki PJ, Ruxrungtham K, Hawkins CA, Wallis CL, Stevens W, van Zyl GU, Manosuthi W, Hosseinipour MC, Ngo-Giang-Huong N, Belec L, Peeters M, Aghokeng A, Bunupuradah T, Burda S, Cane P, Cappelli G, Charpentier C, Dagnra AY, Deshpande AK, El-Katib Z, Eshleman SH, Fokam J, Gody JC, Katzenstein D, Koyalta DD, Kumwenda JJ, Lallemant M, Lynen L, Marconi VC, Margot NA, Moussa S, Ndung'u T, Nyambi PN, Orrell C, Schapiro JM, Schuurman R, Sirivichayakul S, Smith D, Zolfo M, Jordan MR, Shafer RW.Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-lineStavudine-containing antiretroviral therapy: programmatic implications for countries phasing out Stavudine.J Infect Dis. 2013 Jun;207 Suppl 2:S70-7 PMID: 23687292

• Land S, Zhou J, Cunningham P, Sohn AH, Singtoroj T, Katzenstein D, Mann M, Sayer D, Kantor R. Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa.J Int AIDSSoc. 2013 Jul 10PMCID:PMC370936

• Grant PM, Tierney C, Budhathoki C, Daar ES, Sax PE, Collier AC, Fischl MA, Zolopa AR, Balamane M, Katzenstein D.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.HIV Clin Trials. 2013 14(6):284-91. PMID:2433418

• Smith KY, Tierney C, Mollan K, Venuto CS, Budhathoki C, Ma Q, Morse GD, Sax P, Katzenstein D, Godfrey C, Fischl M, Daar ES, Collier AC; ACTG 5202 Study Team Outcomes by Sex following Treatment Initiation with Atazanavir plus Ritonavir or Efavirenz with Abacavir/Lamivudine or Tenofovir/Emtricitabine.Clin Infect Dis. 2014 Feb;58(4):555-63PMID: 24253247

• Katzenstein DA. Editorial Commentary: HIV RNA and Genotype in Resource-Limited Settings: Can We Do Better?Clin Infect Dis. 2014 Jan;58(1):110-2. PMID: 24076967

• KantorR Bettendorf, R Bosch, M Mann, DKatzenstein, S Cu-Uvin, RD’Aquila, L Frenkel, S Fiscus, R Coombs for the ACTG A5077 Study Team HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1–Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077. PLoS One. 2014 Apr 3;9(4) PMID:24699474

• C. H. Shiboski, H. Chen, M. Ghannoum, L. Komarow, S. Evans, P. Mukherjee, N. Isham, D. Katzenstein, A. Asmelash, A. E. Omozoarhe, S. Gengiah, R. Allen, S. Tripathy, S. Swindells.(2014) Role of oral candidiasis in TB and HIV co-infection: AIDS ClinicalTrial Group Protocol A5253.Int J Tuberc Lung Dis. 2014 Jun;18(6):682-8PMID: 24903939

• Manasa J, Danaviah S, Pillay S, Padayachee P, Mthiyane H, Mkhize C, Lessells RJ, Seebregts C, de Wit TF, Viljoen J, Katzenstein D, De Oliveira T. An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings.J Vis Exp. 2014 Mar 30;(85). doi: 10.3791/51242.PMID:24747156

• Wallis C, Aga E, Ribaudo H, Saravanan S, Norton M, Stevens W, Kumarasamy N,Bartlett J, Katzenstein D; on behalf of the A5230 team Drug Susceptibility and Resistance Mutations after First-Line Failure in Resource Limited Settings.Clin Infect Dis. 2014 May 1. PMID: 24795328

• Emily C. Liang, Lindsay Sceats, Nicholas L. Bayless, Dara M. Strauss-Albee, Jessica Kubo Philip M. Grant, David Furman, Manisha Desai, David A. Katzenstein, Mark M. Davis,Andrew R. Zolopa, and Catherine A. Blish. Association between Latent Proviral Characteristics and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected Adults, J Virol. 2014 Aug 1;88(15):8629-8639. Epub 2014 May 21. PMID:24850730

• Anne Derache, Hyoung-shik Shin, Elizabeth White, Dennis Israelski, Jeffrey D. Klausner, Jana Freeman, Maya Balamane and David Katzenstein. HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program